BioSpace News Archive

As part of its ongoing promise to support those living with rare and serious diseases, including bleeding disorders, CSL Behring is donating 500 million international units of coagulation factor therapy to the World Federation of Hemophilia as part of its continued support of the WFH Humanitarian Aid Program.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2022 and reviewed recent business highlights.

Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its expanding pipeline of marketed and investigational therapies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 in Chicago.

The Board of Directors of McKesson Corporation yesterday declared a regular dividend of 47 cents per share of common stock.

Twist Bioscience Corporation announced the launch of the Twist High Throughput Antibody Production, a gene-to-antibody production platform that enables customers to turn candidate DNA sequences into purified antibodies for therapeutic discovery and screening applications.

The global ear nose throat (ENT) treatment market is projected to reach valuation US$ 26.29 Bn by 2029 and is estimated to expand at a CAGR of 6.3% from 2022 to 2030.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11th, 2022.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 5th, 2022.